CMC to manufacture cancer mAb for MacroGenics

By Fiona BARRY

- Last updated on GMT

CMC to manufacture cancer mAb for MacroGenics

Related tags Pharmacology

CMC Biologics, a contract manufacturing organization (CMO), has been picked by biopharmaceutical company MacroGenics to make its oncology candidate as "an extension of their own technical team."

Macrogenics has developed its cell line for the biologic product, and is transferring it to CMC for optimization, to be followed by process development and clinical manufacturing of the drug, CMC told

The company will manufacture the mAb (monoclonal antibody) using a stainless steel bioreactor suite rather than single-use systems, said Stacie Byars, Global Marketing, CMC.

CMC had been chosen for the task, she said, because Macrogenics was looking for an “innovative partner​” CMO which would act as “an extension of their own technical team.​”

OncoSynergy deal

The latest deal is one of several CMC has signed this year for mAb and complex protein development and manufacturing. Most recently it announced an agreement with OncoSynergy for development of its “OS2966” mAb programme, a strategy that aims to inhibit several cancer growth mechanisms with a single drug.

For OncoSynergy, CMC will perform cell-line development, process development, analytical development and manufacturing of non-GMP material, to enable early toxicology testing and cGMP material for IND (investigational new drug) authorization toxicology studies and Phase I clinical trials.

ICH compliance vital for clients

CMC’s Byars told biologics makers turn to outsourcing because of a lack of facilities. “Most biopharmaceutical companies, large and small, do not have the resources – both equipment and technical expertise on staff – to conduct PD [pharmacodynamics] and manufacturing.

However, they ​are very choosy (and should be) about the CMO they choose – ensuring that the CMO of choice has exceptional quality systems and is in compliance with ICH [International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use] regulatory requirements for development and production.​”

CMC has facilities in Copenhagen, Denmark and Seattle, Washington.

Related news

Show more

Related products

show more

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Related suppliers